← United States · All US Insider Profiles
US INSIDER PROFILE · NON-SCORING RESEARCH
Smith Stan
Director
Identity: SEC reporting-owner CIK · Reporting-owner CIK: 0001913199
Purchase history
- Companies traded
- 1
- Purchases · 12M
- 6
- Purchases · 24M
- 14
- Average purchase
- $63.7K
- Median purchase
- $48.4K
- Gross purchase value
- $891.6K
Companies: MAIA Biotechnology, Inc.
14 SEC accession(s) · 0 joint-owner event(s). Values are reported Form 4 transaction values in USD.
Qualifying purchase disclosures
| Published | Company | Ticker | Role | Reported value | SEC source |
|---|---|---|---|---|---|
| 2026-06-02 | MAIA Biotechnology, Inc. | MAIA | Director | $100.5K | Open filing |
| 2026-01-12 | MAIA Biotechnology, Inc. | MAIA | Director | $10.0K | Open filing |
| 2025-12-23 | MAIA Biotechnology, Inc. | MAIA | Director | $69.8K | Open filing |
| 2025-12-09 | MAIA Biotechnology, Inc. | MAIA | Director | $10.9K | Open filing |
| 2025-12-01 | MAIA Biotechnology, Inc. | MAIA | Director | $15.6K | Open filing |
| 2025-11-26 | MAIA Biotechnology, Inc. | MAIA | Director | $24.6K | Open filing |
| 2025-10-02 | MAIA Biotechnology, Inc. | MAIA | Director | $25.0K | Open filing |
| 2025-06-05 | MAIA Biotechnology, Inc. | MAIA | Director | $50.0K | Open filing |
| 2025-05-12 | MAIA Biotechnology, Inc. | MAIA | Director | $100.0K | Open filing |
| 2025-03-05 | MAIA Biotechnology, Inc. | MAIA | Director | $75.0K | Open filing |
| 2025-03-05 | MAIA Biotechnology, Inc. | MAIA | Director | $37.5K | Open filing |
| 2025-02-25 | MAIA Biotechnology, Inc. | MAIA | Director | $75.0K | Open filing |
| 2024-12-13 | MAIA Biotechnology, Inc. | MAIA | Director | $46.8K | Open filing |
| 2024-11-04 | MAIA Biotechnology, Inc. | MAIA | Director | $251.0K | Open filing |
Post-purchase outcomes
Excess return = stock return − S&P 500 ETF (SPY adjusted close) return. Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 14Developing | 100.0% (14/14) | 35.7% (5/14) | -0.4% | +1.8% | -13.8% |
| 20D | 14Developing | 100.0% (14/14) | 50.0% (7/14) | +3.1% | +8.1% | -29.6% |
| 60D | 14Developing | 100.0% (14/14) | 57.1% (8/14) | +1.0% | +5.7% | -39.6% |
| 120D | 13Developing | 100.0% (13/13) | 7.7% (1/13) | -16.7% | -18.6% | -64.7% |
Research patterns
- First purchase in 12M
- 0/13
- Large purchase ≥ $100k
- 2/14
- Cluster buying · 15D
- 11/14
- Buying the dip
- 14/14
Routine / opportunistic: Not classifiable. These labels never affect the score or ranking.
Small samples remain visible but are not scored. This research enrichment never affects US-v1.1.